DIMINISHED PHENYLKETONURIA IN PHENYLPYRUVIC Oligophrenia
AFTER ADMINISTRATION OF L-GLUTAMINE, L-GLUTAMATE
OR L-ASPARAGINE

BY ALTON MEISTER, 2 SIDNEY UDENFRIEND, AND SAMUEL P. BESSMAN

(From the Laboratory of Biochemistry, National Cancer Institute, the Laboratory of Chemical
Pharmacology, National Heart Institute, National Institutes of Health, and the Depart-
ment of Pediatrics, University of Maryland Medical School, Baltimore, Md.)

(Submitted for publication December 27, 1955; accepted February 9, 1956)

It is well known that patients with phenylpyr-
ivic oligophrenia excrete large amounts of phenyl-
pyruvic acid, phenyllactic acid, and phenylalanine
in the urine, and that they also exhibit an unusually
high blood level of phenylalanine (1–4). That
such patients also exhibit a markedly reduced ca-
pacity to convert phenylalanine to tyrosine was in-
dicated by several investigations (2, 5, 6) and was
proven conclusively by isotopic study (7). It
has been suggested that failure to catalyze this re-
action is the basic metabolic defect in this disorder
(6, 7). According to this interpretation, phenyl-
alanine accumulates, and is converted to phenyl-
pyruvic acid and other products in greater than
normal quantities. The finding of abnormally
high concentrations of phenylacetylglutamine in
the urine of patients with phenylpyruvic oligo-
phrenia (8, 9) is also consistent with the increased
accumulation of phenylalanine, with its conversion
to phenylpyruvic acid, and transformation of the
latter compound to phenylacetic acid. In man
the latter compound is excreted in the urine as
phenylacetylglutamine (10–12). It is reasonable
to assume that the chemical defect is responsible
in some way for the mental retardation of these
patients; such an interpretation gains support from
the observation that some patients appear to
show improvement when the dietary phenyl-
alanine intake is restricted (13–16).

It seems probable that the conversion of phenyl-
alanine to phenylpyruvic acid takes place by trans-
amination; this mechanism has been shown to be
responsible for the analogous conversion of tyro-
sine to p-hydroxyphenylpyruvic acid (17–19).
Such a transamination reaction would be expected
to be reversible, so that in the presence of in-
creased concentrations of an appropriate amino
group donor, less phenylpyruvic acid might be
formed. We have therefore attempted to deter-
mine whether an appreciable decrease in the ex-
cretion of phenylpyruvic acid could be effected by
administration of amino acids, such as glutamine,
asparagine, and glutamic acid, which are known
to be active in in vitro transamination systems (20,
21). Although it was not our major purpose to
investigate amino acid administration as a possible
therapeutic measure, it should be pointed out that
reduction of phenylpyruvic acid formation (even
if accompanied by an increase in phenylalanine
concentration) might be a desirable result inasmuch as there is no evidence that phenylalanine
per se is toxic; 3 phenylacetic acid, which is prob-
ably formed from phenylalanine, is known to be
toxic to the central nervous system (23). It may
be noted that several other unusual metabolites of
phenylalanine have been found in the urine of pa-
tients with phenylketonuria (24, 25).

The present studies were also undertaken partly
in an attempt to evaluate the possible involvement
of glutamine in this disorder. The significance of
 glutamine and glutamic acid in brain metabolism
has been emphasized by a number of investiga-
tions (26, 27), and these amino acids are also
known to be widely distributed in other animal
tissues; glutamine is a prominent constituent of
human blood accounting for about one-fifth of the
total amino nitrogen. The increased excretion of
phenylacetylglutamine in phenylpyruvic oligo-

3 It has been found that the tyrosinase activity of mush-
rooms is competitively inhibited by high concentrations
of phenylalanine (22); this observation suggests a
mechanism for the possible toxicity of phenylalanine. In
this connection, it is interesting to note that certain
phenylketonuric patients who received a diet low in
phenylalanine for several months exhibited a darkening of
the hair and skin (13–16).

1 Aided by a grant from the Playtex Park Foundation.
2 Present address: Department of Biochemistry, Tufts
University School of Medicine, Boston, Mass.
phenylalanine might possibly result in a drain of body (and brain) glutamine.

The general plan in the present study was to administer a single dose of a given amino acid, after post-absorptive base-line values had been obtained; the effect of the administered amino acid on the excretion of phenylpyruvic acid and related compounds was followed for several hours. A significant result of these experiments was the observation that administration of glutamine, glutamic acid, or asparagine resulted in a marked reduction in the excretion of phenylpyruvic and phenyllactic acids. On the other hand, there was no demonstrable change in the excretion of phenylacetylglutamine after glutamine administration.

METHODS

The patients studied were two siblings, patient C, an 8-year-old girl weighing 18 kilograms, and patient J, a 7-year-old boy weighing 13 kilograms. Both patients were imbeciles and were known to have excreted large quantities of urinary phenylpyruvic acid for several years. Physical development was normal, and at the time of these studies, they appeared free of other disease. These are the same patients studied previously by Udenfriend and Bessman (7).

The procedure employed in these experiments was as follows: No food was permitted after 8 p.m. on the night prior to the experiment, and urine was collected (by means of an indwelling catheter) at hourly intervals beginning at 3 or 4 a.m. on the following day. At 8 or 9 a.m., the test substance in a dose of 7.6 mM per kilogram of body weight was administered orally or by gastric tube, and urine collections were continued for 6 to 8 hours. Venous blood was drawn by femoral puncture just prior to administration of the test substance and at hourly intervals thereafter. The test substances were given by gastric tube to patient J; in two experiments (Figures 3 (c) and 5). Patient C also received the test compound by gastric tube. Two or three such studies were performed on each patient per week.

Analytical procedures. Phenylpyruvic acid was determined by the procedures of Penrose and Quastel (28) and of Berry and Woolf (29), the latter being more reliable for samples containing relatively low concentrations of phenylpyruvic acid. α-Ketoglutaric acid was determined by densitometric measurement (30) of the corresponding 2,4-dinitrophenylhydrazone after separation from interfering hydrazones by paper chromatography (31). Phenyllactic acid was determined as described by Prescott, Borek, Brecher, and Waelsch (32) after destruction of the phenylpyruvic acid with hydrogen peroxide. In the latter step, the residue, after evaporation of the ether was taken up in 1 ml. of water and treated with 1 ml. of 6 per cent hydrogen peroxide at 37° for 30 minutes. The excess peroxide was decomposed by addition of 0.05 ml. of a crystalline beef liver catalase solution. Control and recovery studies indicated that peroxide treatment removed all of the keto acid without destroying phenyllactic acid. Phenylacetylglutamine was determined (cf. Woolf [8]) as follows: To a 5-ml. sample of urine was added 0.2 ml. of 6N hydrochloric acid and 1.7 gm. of sodium chloride and the mixture was extracted four times with 20 ml. of ethyl acetate. The ethyl acetate fractions were dried over anhydrous sodium sulfate and evaporated; the residue was taken up in 5 ml. of 2N hydrochloric acid and placed in an autoclave (15 lbs. pressure) for one hour. The resulting solution was neutralized and analyzed for glutamate with glutamic acid decarboxylase (33). The recovery of glutamate from known solutions of phenylacetylglutamine in water or urine was 85 to 95 per cent. Phenylalanine was determined by the method

![Fig. 1. Effect of Administration of L-Glutamine on Urinary Excretion of Phenylpyruvic Acid (ΦPy), Phenylacetylglutamine (ΦACGM), Phenyllactic Acid (ΦLA), and α-Ketoglutaric Acid (KG), and on the Blood Levels of Glutamine (GM) and Glutamic Acid (GA)](image)

A dose of 137 mM of L-glutamine (7.6 mM per kilogram) was administered at the time indicated by the arrow (Patient C).
AMINO ACID ADMINISTRATION IN PHENYLPYRUVIC Oligophrenia

Fig. 2. Effect of Two Doses, Each 7.6 mM per Kilogram of Body Weight, of L-Glutamine on Urinary Excretion of Phenylpyruvic Acid (φPY), Phenylacetylglutamine (φACGM), Phenyllactic Acid (φLA) and α-Ketoglutaric Acid (KG) Patient C

Fig. 3. Effect of L-Glutamine (Patient C), Sodium L-Glutamate (Patient J), and Glycine (Patient C) on Urinary Excretion of Phenylpyruvic Acid

The authors are indebted to Dr. Karl Pfister and Dr. Nathaniel Ritter of Merck and Company, and to Dr. B. Vassel and Dr. M. J. Blish of International Minerals and Chemical Corporation for generous amounts of L-glutamate and sodium L-glutamate. They also wish to thank Dr. Ruth Baldwin of the Department of Pediatrics, University of Maryland Medical School for the L-asparagine used in these investigations.
such, although the rise in blood glutamic acid is consistent with the occurrence of some deamination. This suggests that glutamine is absorbed unchanged from the human intestine. Similar results have been reported in the cat (35). When two doses of glutamine were given (Figure 2), the results were similar, although the changes were more marked. In this experiment, the decrease in phenylpyruvic acid excretion was also prompt, reaching a value equivalent to approximately 23 per cent of the control level four hours after the initial dose. There was no return to the control level of excretion eight hours after the initial dose of glutamine was given. Again, a considerable reduction in phenyllactic acid excretion occurred, and about a two-fold increase in α-ketoglutarate excretion was observed. There was no significant change in the excretion of phenylacetylglutamine.

Separate studies were carried out in which equi-

molar quantities of sodium L-glutamate, glycine, sodium succinate, and glucose were administered. Of these compounds, only sodium L-glutamate had a significant effect on phenylpyruvic acid excretion. A comparison of the results obtained in experiments in which sodium L-glutamate, glycine, and L-glutamine were administered is presented in Figure 3. The excretion fell to about one-third of the control level after glutamine administration, to about two-thirds of this value after glutamate was given, and no effect was observed with glycine. Phenylacetylglutamine excretion was not significantly affected by any of the amino acids.

Figures 4 and 5 summarize experiments in which L-asparagine was administered. As in the studies with glutamine and glutamate, there was a significant reduction of phenylpyruvic acid excretion. The level of excretion fell to 60 or 70 per cent of the control value. It is of some interest, however, that control levels of phenylpyruvic acid excretion were observed for the first 2 or 3 hours. This is in distinct contrast to the prompt decrease in excretion observed after glutamine and gluta-
Phenylactic acid probably arises by reduction of phenylpyruvic acid, and the observed decrease in excretion of this hydroxy acid may therefore be ascribed to the decrease in phenylpyruvic acid.

It might be anticipated, in accordance with reaction (2), that decreased formation of phenylpyruvic acid due to glutamine or glutamate administration, would be associated with an increase of α-ketoglutaric acid and phenylalanine. Although an increase in α-ketoglutarate excretion was observed in the studies with glutamine, no consistent elevation of the excretion of phenylalanine or of its blood level was observed. In one experiment there was a slight rise in the blood level of phenylalanine one hour after glutamine was given; however, this was not observed in other studies, and we are reluctant to conclude from our present data that the phenylalanine blood level has been demonstrated to increase. It is possible that an evanescent rise does indeed occur, but that the extra phenylalanine formed is rapidly diluted by the body fluids. Assuming that patient C has a total body fluid volume of 12 liters, and that a quantity of 120 μM of phenylalanine (equivalent to the maximum total hourly deficit in phenylpyruvic acid excretion) is formed at one time, we have calculated that the blood level of phenylalanine would increase by only 1 μM per 100 ml. This represents a change of less than 1 per cent in the blood level of phenylalanine, which is well within the range of experimental error of the procedure employed. Such a change would actually be expected to occur over a period of time which would make it even more difficult to detect. Any uptake of phenylalanine by cells would further minimize the rise in blood phenylalanine.

A decrease in phenylacetylglutamine excretion was not observed, even in association with a large reduction of phenylpyruvic acid excretion (Figure 2). Furthermore, the available data do not permit the conclusion that phenylacetylglutamine excretion increased significantly as a result of glutamine administration. This finding suggests that there is no deficiency of glutamine for the coupling reaction, and indicates that the observed decrease in phenylpyruvic acid excretion cannot be explained in terms of increased phenylacetylglutamine formation. The reason for the relatively constant rate of excretion of phenylacetylglutamine is not apparent; the mechanism of its formation,
and the question of the formation of phenylacetic acid require further study.

Asparagine administration also produced a reduction of phenylpyruvic acid excretion; however, it is of interest that the decrease did not occur immediately following administration as in the case of glutamine and glutamate, but occurred after a lag of several hours. Furthermore, asparagine administration was associated with a considerable rise in the blood levels of glutamine and glutamate as well as in asparagine itself. The findings suggest that asparagine is rapidly metabolized and that its effect may be due to conversion to glutamine. It has been found in other studies (38), that administration of asparagine to normal children leads to increased blood levels of glutamine, without significant change of blood aspartate levels. An investigation of the apparent conversion of asparagine to glutamine would be desirable.

The greater effectiveness of glutamine as compared to glutamate in producing a decrease in the excretion of phenylpyruvic acid may be due to the participation of glutamine itself in transamination (20) or to the fact that glutamine may pass more readily through the cell membranes (cf. [26]). On the other hand, it is also possible that glutamate is the major active amino donor and that glutamine provides glutamate directly by deamidation and also by incorporation of its amide nitrogen into \( \alpha \)-ketoglutarate.

It may be concluded that the reduction of phenylpyruvic acid excretion following administration of glutamine, asparagine, or glutamate is consistent with, but does not prove, a transamination mechanism. There are a number of other lines of evidence also consistent with the occurrence of active transamination \textit{in vivo}. These include the rapid incorporation of \(^{15} \text{N}\)-amino acid nitrogen into almost all of the amino acids of the rat (39), and the ability of animals to grow on diets containing the \( \alpha \)-keto acid analogues of certain essential amino acids, cf. (21). It has also been observed that administration of glutamate to animals leads to an increase in the blood levels of \( \alpha \)-ketoglutarate and alanine, and a decrease in the blood level of pyruvate (40, 41).

The present findings appear to have significance in terms of the mechanism of the metabolic defect in phenylpyruvic oligophrenia. It appears unlikely that there is a serious loss of glutamine from the body in this disorder. The present suggestion as to the role of transamination in this disease may possibly have therapeutic implications. Although the administration of glutamic acid over a period of several weeks (and in conjunction with a regular diet) did not affect phenylketonuria (42), the possibility of administering large amounts of glutamine together with a diet low in phenylalanine should be considered. It has been suggested that urinary phenylpyruvate arises in the kidney (4), and it is probable that phenylpyruvate is formed by transamination in most of the other tissues of the body, cf. (21). It is known that circulating glutamine promptly reaches the tissues (including the brain [43]); maintenance of a sufficiently high tissue concentration of glutamine might serve to reduce phenylpyruvate formation in the brain and other tissues. The present findings suggest that glutamine lowers phenylpyruvate formation in the kidney, and are entirely consistent with a similar effect in other tissues. The greater availability of glutamine in recent months at relatively low cost may make feasible a long-term investigation of this problem.

**SUMMARY**

1. Two phenylketonuric patients were given single oral doses of L-glutamine, sodium L-glutamate, L-asparagine, glycine, sodium succinate or D-glucose, and the urinary excretion of phenylpyruvic acid was measured for several hours prior to and after administration of the test compound.

2. After glutamine was given, the excretion of phenylpyruvic and phenyllactic acids decreased to about one-third of the control level. Glutamate and asparagine also lowered phenylpyruvic acid excretion, although the effect was not as great as that observed with glutamine. No significant changes were observed in the excretion of phenylacetylglutamine or in the blood levels or urinary excretion of phenylalanine. The excretion of \( \alpha \)-ketoglutarate was increased after glutamine administration.

3. In contrast to the findings after glutamine and glutamate were given, the effect of asparagine on phenylpyruvic acid excretion occurred after a lag period. Since asparagine also led to increased blood levels of glutamine, it is possible that the effect of asparagine in lowering phenyl-
pyruvic acid excretion is mediated through glutamine.

4. The results are discussed in terms of the concept that transamination plays a role in phenylpyruvic oligophrenia.

ACKNOWLEDGMENT

The authors wish to acknowledge the skillful technical assistance of Miss Patricia A. Abendschein, Mr. Samuel Seymour, Mr. Ennis C. Layne, and Mrs. P. Fraser Downey.

REFERENCES


38. Bessman, S. P., Unpublished observations.


42. Woolf, L. I., and Vulliamy, D. G., Phenylketonuria with a study of the effect upon it of glutamic acid. Arch. Dis. Childhood, 1951, 26, 487.